News Cencora - Largest Companies by Marketcap, Revenue, Net Income and Employees

COR's MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal

19.02.2026 12:56

Cencora is set to merge MWI Animal Health with Covetrus in a $3.5B deal, retaining a 34.3% stake as it unlocks capital and targets animal health growth.

Is the Options Market Predicting a Spike in Cencora Stock?

17.02.2026 13:52

Investors need to pay close attention to COR stock based on the movements in the options market lately.

Cencora Closes $3.0 Billion Senior Notes Offering

13.02.2026 21:15

CONSHOHOCKEN, Pa., February 13, 2026--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the "2029 Notes"), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the "2030 Notes"), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the "2033 Notes"), $1.0 billion aggregate principal amount of its 4.900% S

Cencora (COR) Valuation Check After Strong Multi‑Year Shareholder Returns

12.02.2026 13:10

Cencora (COR) has moved higher recently. With the shares last closing at $365.70, many investors are revisiting the pharmaceutical distributor’s long term return profile and current valuation signals. See our latest analysis for Cencora. The recent 1 day share price return of 1.58% and 7 day share price return of 10.83% sit against a far stronger long term picture, with 1 year total shareholder return of 51.29% and 5 year total shareholder return of 265.50%, suggesting momentum has been...

1 Momentum Stock with Impressive Fundamentals and 2 We Question

12.02.2026 04:37

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

5 Revealing Analyst Questions From Cencora’s Q4 Earnings Call

11.02.2026 05:36

Cencora's fourth quarter was marked by a negative market reaction, as revenue missed Wall Street’s expectations despite year-over-year growth. Management attributed performance to continued growth in its U.S. healthcare solutions, particularly specialty pharmaceuticals and new contributions from recent acquisitions. CEO Robert Mauch emphasized the impact of enhanced operational capabilities and highlighted the integration of Retina Consultants of America (RCA) and the completion of the OneOncolo

Chief Executives for Corporate Purpose Announces Covista Chairman and CEO Steve Beard, Cencora Inc. Former Executive Chair Steven H. Collis, and Ann Fairchild, interim President and CEO of Siemens USA Joining Board of Directors

09.02.2026 15:30

NEW YORK CITY, NY / ACCESS Newswire / February 9, 2026 / Chief Executives for Corporate Purpose® (CECP) announced today that three distinguished executives will join the organization's Board of Directors: Steve Beard, Chairman and CEO of Covista, ...

Is It Too Late To Consider Cencora (COR) After A 46% One-Year Rally?

08.02.2026 07:04

If you are wondering whether Cencora's current share price still offers value, you are not alone. The stock has attracted a lot of attention from investors trying to work out what a fair price really looks like. Cencora's shares recently closed at US$359.25, with returns of 0.0% over 7 days, 7.0% over 30 days, 6.0% year to date, 46.0% over 1 year, 131.5% over 3 years and 259.5% over 5 years. This naturally raises questions about how much future upside or risk is now priced in. Recent...

Cencora Q1 Earnings Call Highlights

05.02.2026 06:13

Cencora (NYSE:COR) reported a strong start to fiscal 2026 and raised key elements of its full-year outlook after completing the acquisition of a majority stake in OneOncology. Management highlighted continued momentum in the company’s U.S. Healthcare Solutions segment, benefits from its pharmaceutic

Cencora (COR) Q1 2026 Earnings Call Transcript

04.02.2026 15:04

Hi, everyone, and thank you for joining Cencora's fiscal 2026 first quarter earnings call. In 2026, we delivered adjusted operating income growth of 12% and adjusted diluted EPS growth of 9%, driven by our market-leading capabilities. To reflect our performance, and the contribution from our recently completed acquisition of OneOncology, we are raising our fiscal 2026 guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%.

Cencora (COR) Q1 Earnings Top Estimates

04.02.2026 12:40

Cencora (COR) delivered earnings and revenue surprises of +0.35% and -0.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cencora (NYSE:COR) Misses Q4 CY2025 Revenue Estimates

04.02.2026 11:47

Healthcare distributor Cencora (NYSE:COR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 5.5% year on year to $85.93 billion. Its non-GAAP profit of $4.08 per share was 1% above analysts’ consensus estimates.

Cencora: Fiscal Q1 Earnings Snapshot

04.02.2026 11:38

CONSHOHOCKEN, Pa. AP) — Cencora, Inc. COR) on Wednesday reported fiscal first-quarter profit of $559.6 million.

Cencora Reports Fiscal 2026 First Quarter Results

04.02.2026 11:30

CONSHOHOCKEN, Pa., February 04, 2026--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below

Cencora, Inc. 2026 Q1 - Results - Earnings Call Presentation

04.02.2026 09:49

2026-02-04. The following slide deck was published by Cencora, Inc.

Cencora (COR) Reports Earnings Tomorrow: What To Expect

03.02.2026 03:06

Healthcare distributor Cencora (NYSE:COR) will be reporting results this Wednesday before market open. Here’s what to look for.

How Investors May Respond To Cencora (COR) Deepening Its Rare Disease Services Through Curant Collaboration

31.01.2026 07:05

On January 22, 2026, Curant Health’s Curant Rare announced a collaboration with Cencora that combines Cencora’s commercialization and logistics capabilities with Curant Rare’s specialty pharmacy and patient-engagement services to support rare disease therapies. This partnership is designed to give rare disease drug developers integrated access to real-world evidence, patient-reported outcomes and market access support, aiming to smooth complex regulatory and access hurdles. With growing...

Exploring Analyst Estimates for Cencora (COR) Q1 Earnings, Beyond Revenue and EPS

30.01.2026 14:15

Besides Wall Street's top-and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.